Breakthrough Bleeding on the Contraceptive Patch: Causes & Management
Breakthrough bleeding (BTB) — unscheduled spotting/bleeding — is common in the first 3–6 months of combined hormonal contraceptive (CHC) use, including the transdermal patch (EE/NGMN).
Expected Pattern
- Months 1–3: Up to 30–50% experience BTB.
- Months 3–6: Declines significantly.
- >6 months: Persistent BTB warrants evaluation.
Common Causes
| Category | Mechanism / Examples |
|---|---|
| Hormonal Adaptation | Endometrial stabilization to steady EE/progestin; thin atrophic lining → fragile vessels |
| Non-Adherence | Late patch change (>24h), detachment, incorrect placement, skipping patch-free week |
| Drug Interactions | Enzyme inducers: rifampin, griseofulvin, carbamazepine, phenytoin, topiramate (>200mg), St. John's wort → ↓ EE levels |
| GI Malabsorption | Not relevant for transdermal (bypasses gut) — advantage over OCPs |
| Underlying Pathology | Cervicitis (GC/CT), endometrial polyp, fibroid (submucosal), adenomyosis, cervical dysplasia, endometrial hyperplasia/cancer (rare) |
| Pregnancy | Implantation bleeding, subchorionic hematoma, ectopic — rule out with hCG |
